Stocks to be on your radar: Tata Motors, Claris, Aurobindo

Macquarie has an outperform on Tata Motors. The house has raised target price to Rs 600 from Rs 535 earlier. According to the hosue, last quarter saw a steady performance with a JLR being the key positive. CLSA has a buy on Tata Motors with a raised target price to Rs 635 versus Rs 545 earlier. JLR margins dragged down by forex losses. Expect strong rebound in margins in FY17 and FY18. Upgrade FY17-18 EPS by 4-6 percent. CLSA view on Infosys: Cut target from Rs 1,200 to Rs 1,120 (16 times June-18). Guidance revision delayed, even as downside risks increase. Downside risks to guidance, strategy unchanged; Few positives.Deutsche Bank view on Infosys: Elevated risk of another guidance cut. Maintain hold with target at Rs 1,080. Q2 worse than anticipated; though better than Q1.Aurobindo Pharma: Report says Aurobindo & Intas final contenders for Teva's UK & Irish portfolio. Teva selling portfolio to comply with EU anti-trust regulations. Aurobindo & Intas have submitted offers of around USD 1 bn on Friday. Other Bidders: Private Equity Interests from Cinven, Mylan, Apollo Global Mgmt LLC, Novartis. Torrent seems to have backed out of the race. Any fund raising plans would only be for strategic purposes. Net debt at USD 525 m as of Q1, co plans to scale it down to USD 500 million. Rubber prices fall: Prices decline to Rs 130/kg as on August 27, 2016. Prices now down 9.8 percent since August 1, 2016. Prices now lowest since June 21, 2016. Fall in rubber prices positive for tyre makers. Natural rubber accounts for 40 percent of raw material cost for tyre manufacturers. Every fall in prices impacts the profitability of the ind positively by Rs 60 crore. Decline in natural rubber prices in major overseas markets. Higher imports, Favourable weather. Progress in tapping activities in Kerala. Rubber board indicates production rise of 6.4 percent in June & 2.3 percent in Q1. Claris Life: Claris Life gets 5 observations from US FDA post inspection at its injectible facility in Vasna, Gujarat. US FDA inspection conducted from August 16-26 on plant 1 of the manufacturing facility. Was PAI (Prior Approval Inspection) to approve ANDAs that co has applied for. Claris Life received approval for Flumazenil Injection post the PAI inspection. Flumazenil Injection: Market size small at USD 4 million. Company getting approval signals the observations could be benign. Analysts will watch for the US FDA approval being rescinded. Claris Life has a total of 16 approvals and over 20 ANDAs under approval with market size of USD 2 bn. GMR Infra: GMR Airports wins contract for North Goa's greenfield Mopa airport. Airport to be built on build-operate- transfer model for a period of 40 years. BOT period extendable by 20 years. Airport to have hybrid till with 30 percent cross subsidy. Letter of award is expected to be issued within 60 days.Future Retail: Future Retail to list today. Under scheme of arrangement, co was divided into Future Ent & Bharti Retail. Fron-end business are operations of Big Bazaar, Easy Day, Home Town, Food Hall. Company will pay lease rentals to back-end entity i.e. Future Enterprise. Combined market cap of back-end & front-end business pre-demerger was Rs 6,000 crore. Future Enterprise already listed with market cap of Rs 850 crore. New market cap could be around Rs 6,600 crore. Outstanding shares: 47.2 crore shares. Stock could open around Rs 140-150.